AGROAMERICA
AgroAmerica, a globally recognized sustainable company, has been invited since 2017 to sponsor the Central American Donors Forum , an initiative of the Seattle International Foundation (SIF), to generate alliances and advance in development efforts in Central America to generate a greater social impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005525/en/
The Forum has the participation of over 400 leaders from business, government, private sector, media outlets, and civil society, as well as international and regional panelists, to discuss priority issues and promote Social Responsibility. For the first time since its inception, the 2020 Forum was held virtually and was open to all audiences.
From September 1 - 3, 2020, the interventions of the different Forum participants focused on the “Reinvention and resistance in times of crisis” . The COVID-19 pandemic has exposed many of the vulnerabilities and concerns of Central America based on the construction of alternative responses to the economic impact, gender approach, migration, and the role of companies to increase market access for all.
Promoting development:
For the 4th consecutive year, AgroAmerica participated as a sponsor of the Forum, promoting the development of the Central American region and the implementation of good business, labor, social and environmental practices.
During 2019, the Forum's central theme was “Progress at the Crossroads”. More than 30 conferences, panels, and workshops were held in Tegucigalpa, Honduras, addressing Economic Development, Youth, Feminist Movements, Corruption, Migration, Human Rights, Democracy, Public-Private Partnerships, among others.
In 2018, the forum was held in San Salvador, El Salvador, developing the theme “Creating space for everyone”, highlighting the role of corporate social responsibility in building a more inclusive region through strategic alliances with social actors.
In 2017, AgroAmerica CEO, Fernando Bolaños, was a member of the host committee, as well as a panelist of the Forum that revolved around the theme “Reimagining Partnerships” held in Panama City.
Bolaños participated on the panel Social Responsibility: The Role of Influential People in the Construction of Democracy in Central America . “There are many challenges facing Central America,” said Bolaños during his intervention. “Our challenges are all connected and linked – food security, poverty, gender equality, health and education to name just a few. At AgroAmerica we strive to create a sustainable development initiative through partnerships, so we can improve the lives of our employees and the people in the surrounding communities.”
AgroAmerica will continue contributing to initiatives that promote a more inclusive region through its Corporate Sustainability Strategy and strategic alliances with social actors.
About AgroAmerica:
AgroAmerica is an agroindustrial corporation dedicated the production and commercialization of food products, using sustainable and responsible farming methods. With operations in Europe, United States, México, Guatemala, Ecuador, Perú, and Panamá. AgroAmerica operates based on a Corporate Sustainability strategy to generate value and balance among economic growth, natural resource conservation, and our customers and stakeholders wellbeing. Visit us: https://agroamerica.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005525/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
